Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa

被引:4
作者
Kulisevsky, Jaime [1 ,2 ]
Bejr-Kasem, Helena [1 ,2 ]
Martinez-Horta, Saul [1 ,2 ]
Horta-Barba, Andrea [1 ,2 ]
Pascual-Sedano, Berta [1 ,2 ,3 ]
Campolongo, Antonia [1 ,2 ,3 ]
Marin-Lahoz, Juan [1 ,2 ]
Aracil-Bolanos, Ignacio [1 ,2 ]
Perez-Perez, Jestjs [1 ,2 ]
Izquierdo-Barrionuevo, Cristina [1 ,2 ]
de Fabregues, Oriol [4 ]
Puente, Victor [5 ]
Crespo-Cuevas, Ane [6 ]
Calopa, Matilde [7 ]
Pagonabarraga, Javier [1 ,2 ]
机构
[1] Hosp Santa Creu & Sant Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
[2] Univ Autonoma Barcelona UAB, Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Inst Invest Biomed St Pau IIB St Pau, Barcelona, Spain
[3] Univ Oberta Catalunya UOC, Fac Hlth Sci, Barcelona, Spain
[4] UAB, Neurodegenerat Dis Res Grp, Vall dHebron Univ Hosp, Movement Disorders Unit,Vall dHebron Res Inst,Neu, Barcelona, Spain
[5] UAB, Inst Municipal Invest Med, Neurol Dept, Hosp Mar, Barcelona, Spain
[6] UAB, Dept Neurosci, Hosp Univ Germans Trias & Pujol, Barcelona, Spain
[7] Hosp Univ Bellvitge, Neurol Serv, Barcelona, Spain
关键词
Parkinson's disease; Levodopa; carbidopa intestinal gel; Pharmacokinetics; Non-motor fluctuations; Mood; Anxiety; Executive function; CARBIDOPA INTESTINAL GEL; NONMOTOR FLUCTUATIONS; MOTOR FLUCTUATIONS; MOOD FLUCTUATIONS; RATING-SCALE; INFUSION; DOPAMINE; DYSKINESIAS; PERFORMANCE; DYSFUNCTION;
D O I
10.1007/s00415-020-10018-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Chronic levodopa treatment in Parkinson's disease (PD) may promote undesirable motor and non-motor fluctuations. Compared to chronic oral levodopa treatment, continuous infusion of levodopa/carbidopa intestinal gel (LCIG) in advanced PD reduces motor fluctuations. However, differences in their effect on acute non-motor changes were not formally demonstrated. Objective We performed a randomized, double-blind, double-dummy, crossover study to compare acute non-motor changes between intermittent oral immediate-release carbidopa/levodopa (LC-IR) and LCIG. Methods After > 12-h OFF, thirteen PD patients chronically treated with LCIG and without history of non-motor swings, were allocated to receive first, LCIG infusion plus three oral doses of placebo, or placebo infusion plus three oral doses of LC-IR. Over-encapsulated oral medication (LC-IR or placebo) was administered every 2 h. We monitored plasmatic levels of levodopa, motor status (UPDRS-III), mood, anxiety, and frontal functions at baseline (0-h) and hourly after each oral challenge. Results Repeated-measures ANOVAs showed significant group by treatment interaction indicating more fluctuations of levodopa plasma levels with LC-IR. No significant interactions were seen in the temporal profile of motor status, anxiety, mood and cognition. However, point-to-point parametric and nonparametric tests showed a significant more marked and more sustained improvement in anxiety scores under LCIG. A significant improvement of mood and verbal fluency was seen a + 3-h only under LCIG. Discussion Our sample of advanced PD patients exhibited moderate but significant non-motor fluctuations. LCIG was associated with a more favorable profile of acute affective and cognitive fluctuations that was particularly expressed at the first part of the infusion curve.
引用
收藏
页码:3400 / 3410
页数:11
相关论文
共 50 条
  • [41] Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
    Ferreira, Joaquim J.
    Lees, Andrew
    Rocha, Jose-Francisco
    Poewe, Werner
    Rascol, Olivier
    Soares-da-Silva, Patricio
    LANCET NEUROLOGY, 2016, 15 (02) : 154 - 165
  • [42] Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa
    Rabey, JM
    Sagi, I
    Huberman, M
    Melamed, E
    Korczyn, A
    Giladi, N
    Inzelberg, R
    Djaldetti, R
    Klein, C
    Berecz, G
    CLINICAL NEUROPHARMACOLOGY, 2000, 23 (06) : 324 - 330
  • [43] The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study
    Snow, BJ
    Macdonald, L
    Mcauley, D
    Wallis, W
    CLINICAL NEUROPHARMACOLOGY, 2000, 23 (02) : 82 - 85
  • [44] Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
    Ferreira, Joaquim J.
    Poewe, Werner
    Rascol, Olivier
    Stocchi, Fabrizio
    Antonini, Angelo
    Moreira, Joana
    Pereira, Ana
    Rocha, Jose-Francisco
    Soares-da-Silva, Patricio
    NEUROLOGY AND THERAPY, 2022, 11 (03) : 1409 - 1425
  • [45] Effects of Unilateral Stimulation in Parkinson's Disease: A Randomized Double-Blind Crossover Trial
    Zeng, Zhitong
    Wang, Linbin
    Shi, Weikun
    Xu, Lu
    Lin, Zhengyu
    Xu, Xinmeng
    Huang, Peng
    Pan, Yixin
    Chen, Zhonglue
    Ling, Yun
    Ren, Kang
    Zhang, Chencheng
    Sun, Bomin
    Li, Dianyou
    FRONTIERS IN NEUROLOGY, 2022, 12
  • [46] Theta-Burst Stimulation for Cognitive Enhancement in Parkinson's Disease With Mild Cognitive Impairment: A Randomized, Double-Blind, Sham-Controlled Trial
    Lang, Stefan
    Gan, Liu Shi
    Yoon, Eun Jin
    Hanganu, Alexandru
    Kibreab, Mekale
    Cheetham, Jenelle
    Hammer, Tracy
    Kathol, Iris
    Sarna, Justyna
    Martino, Davide
    Monchi, Oury
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [47] Evaluation of acupuncture in the treatment of Parkinson's disease: A double-blind pilot study
    Cristian, A
    Katz, M
    Cutrone, E
    Walker, RH
    MOVEMENT DISORDERS, 2005, 20 (09) : 1185 - 1188
  • [48] Selegiline as the primary treatment of Parkinson's disease - A long-term double-blind study
    Myllyla, VV
    Sotaniemi, KA
    Hakulinen, P
    MakiIkola, O
    Heinonen, EH
    ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (04): : 211 - 218
  • [49] Opicapone OCEAN study in Parkinson's: design of a randomized double-blind placebo-controlled trial
    Chaudhuri, K. Ray
    Odin, P.
    Ferreira, J.
    Antonini, A.
    Rascol, O.
    Kurtis, M.
    Storch, A.
    Bannister, K.
    Costa, R.
    Magalhaes, D.
    Rocha, J. F.
    Soares-da-silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 902 - 902
  • [50] Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson's Disease
    Bronzova, Juliana
    Sampaio, Cristina
    Hauser, Robert A.
    Lang, Anthony E.
    Rascol, Olivier
    Theeuwes, Ad
    van de Witte, Serge V.
    van Scharrenburg, Guus
    MOVEMENT DISORDERS, 2010, 25 (06) : 738 - 746